Checkpoint blockade treatment sensitises relapsed/refractory non‐Hodgkin lymphoma to subsequent therapy

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

(2019) Stephen M. Ansell et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

(2019) John P. Leonard et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers

(2018) Cédric Rossi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer

(2018) Song Ee Park et al.   Journal of Thoracic Oncology

Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors

(2018) Elizabeth A. Kuczynski et al.   MOLECULAR CANCER THERAPEUTICS

Overall survival (OS) and transplantation (ASCT) utilization in real-world patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL).

(2018) Chadi Nabhan et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.

(2018) Khalil Saleh et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses

(2018) Rafael Cubas et al.   JOURNAL OF IMMUNOLOGY

Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-Cell lymphoma in the United States

(2018) Joshua A. Roth et al.   JOURNAL OF MEDICAL ECONOMICS

New developments in immunotherapy for lymphoma

(2018) Heyman Benjamin et al.   Cancer Biology & Medicine

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

(2016) E Van Den Neste et al.   BONE MARROW TRANSPLANTATION

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

(2015) J. Kuruvilla et al.   BLOOD

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era

(2013) Sarah J. Nagle et al.   AMERICAN JOURNAL OF HEMATOLOGY

Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer

(2013) Rupal Ramakrishnan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies

(2013) Mark Chao   Cancer Management and Research